1,3-Oxazine-2-one derived dual-targeted molecules against replicating and non-replicating forms of Mycobacterium tuberculosis

Eur J Med Chem. 2020 Dec 15:208:112835. doi: 10.1016/j.ejmech.2020.112835. Epub 2020 Sep 13.

Abstract

The high mortality rate and increasing prevalence of resistant Mtb are the major concerns for the Tuberculosis (TB) treatment in this century. To curtail the prevalence of resistant Mtb, we have prepared 1,3-oxazine-2-one based dual targeted molecules. Compound 67 and 68 were found to be equally active against replicating and non-replicatiing form of Mtb (MICMABA 3.48 and 2.97 μg/ml; MICLORA 2.94 and 2.15 μg/ml respectively). They had found to suppress the biosynthesis of alfa, methoxy and keto-mycolate completely, as well as inhibit enzymatic activity of MenG (IC50 = 9.11 and 6.25 μg/ml respectively for H37Ra; IC50 = 11.76 and 10.88 μg/ml respectively for M smegmatis).

Keywords: 1,3-Oxazine-2-one; MenG enzyme; Mycobacterium tuberculosis; Mycolic acid.

MeSH terms

  • Antitubercular Agents / chemical synthesis
  • Antitubercular Agents / pharmacology*
  • Antitubercular Agents / toxicity
  • Bacterial Proteins / antagonists & inhibitors
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / toxicity
  • Leukocytes, Mononuclear / drug effects
  • Methyltransferases / antagonists & inhibitors
  • Microbial Sensitivity Tests
  • Molecular Structure
  • Mycobacterium smegmatis / drug effects
  • Mycobacterium tuberculosis / drug effects*
  • Mycolic Acids / metabolism
  • Oxazines / chemical synthesis
  • Oxazines / pharmacology*
  • Oxazines / toxicity
  • Structure-Activity Relationship

Substances

  • Antitubercular Agents
  • Bacterial Proteins
  • Enzyme Inhibitors
  • Mycolic Acids
  • Oxazines
  • Methyltransferases